Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

Affiliations

• ¹ Medical Department B, Division of Hepatology, Gastroenterology, Oncology, Hematology, Palliative Care, Endocrinology, and Diabetes, Brandenburg Medical School, University Hospital Ruppin-Brandenburg, Neuruppin, Germany.
• ² Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam, Potsdam, Germany.
• ³ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
• ⁴ Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
• ⁵ Lipidomix, Berlin, Germany.
• ⁶ Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany.
• ⁷ Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain.
• ⁸ Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
• ⁹ Department of Digestive Oncology, University Hospitals Leuven, Leuven, Belgium.
• ¹⁰ Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
• ¹¹ Radiology Department, Grenoble University Hospital, La Tronche, France.
• ¹² Department of Radiology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
• ¹³ Chair of Food Chemistry, Faculty of Mathematics and Natural Science, University of Wuppertal, Wuppertal, Germany.
• ¹⁴ Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.